Lysergic acid diethylamide
- Generic Name
- Lysergic acid diethylamide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25N3O
- CAS Number
- 50-37-3
- Unique Ingredient Identifier
- 8NA5SWF92O
- Background
Debate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder. Many emotionally intense experiences can lead to flashbacks when a person is reminded acutely of the original experience. However, not all published case reports of chronic flashbacks appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder.
- Associated Conditions
- -
- Associated Therapies
- -
What the FDA’s groundbreaking guidance really means for psychedelic therapy clinical trials
Psychedelic therapy shows promise for treating mental health conditions like PTSD, anxiety, and depression, with long-term benefits. The FDA has issued guidance for psychedelic drug development, emphasizing psychotherapy integration, patient safety, and rigorous data collection. This marks a significant shift towards recognizing and expanding psychedelic therapy's potential in mental healthcare.
Minnesota Psychedelics Task Force Urges Lawmakers To Decriminalize Psilocybin
A Minnesota task force recommends decriminalizing psilocybin mushrooms for personal use and establishing a therapeutic access program. It also suggests funding research into psilocybin, MDMA, and LSD. The recommendations aim to provide equitable access and safety, reflecting a broader movement towards psychedelic reform.
Minnesota task force recommends decriminalizing 'magic' mushrooms
Mushrooms, MDMA, and LSD are prioritized for decriminalization due to their potential therapeutic benefits, including treating anxiety, PTSD, depression, and substance use disorders. These substances may offer more effective treatment by addressing root causes of symptoms.
Psychedelic drug therapy may address mental health
Psilocybin, combined with psychotherapy, significantly improves mental health in cancer patients and induces lasting positive personality changes in those with alcohol use disorder, as per studies published in Nature Mental Health and The American Journal of Psychiatry. Benefits include reduced anxiety, depression, and impulsiveness, with effects lasting up to seven months. Research emphasizes psilocybin's safety under medical supervision.
Psychedelic treatment and mental health: Navigating a longer trip with optimism
Psychedelics disrupt neural pathways, enhancing brain plasticity and aiding in overcoming mental health conditions. They impair hippocampal episodic memory but enhance cortical familiarity memory. Psychedelics may reopen critical learning periods, promoting new behaviors, emphasizing the need for therapeutic guidance.
Psychedelic therapy: Will it be a game changer for mental health
Interest in psychedelic therapy has surged, with Oregon and Colorado legalizing psilocybin and Australia recognizing psychedelics as medicines. Research explores their use for mental health disorders, with MDMA and psilocybin showing promise for PTSD and depression. Legal and access issues remain, alongside concerns over equity in research participation and treatment access.
Top Findings on Addiction in 2024
Substance use disorders (SUDs) are a global issue, with research in 2024 highlighting key findings: a rise in drug overdose deaths, primarily from synthetic opioids; the ineffectiveness of certain interventions in reducing opioid deaths; neurological impacts of non-fatal overdoses; potential of psychedelics like ibogaine for treating PTSD and addictions; cannabis use's negative impact on academic achievement; prevalence of polysubstance use; advances in understanding behavioral addictions; genetic links between cannabis use and other SUDs; therapeutic effects of psilocybin on brain connectivity; and parallels between food and drug addiction mechanisms.
Coloradans will have a new psychiatric treatment option in psilocybin on Jan. 1
Ryan Chrapko transformed his life using psilocybin, moving from substance abuse to mental health improvement. Colorado's Proposition 122 now allows clinical psychedelic use, offering therapeutic benefits for conditions like PTSD and depression, with professional guidance enhancing outcomes.
Ayahuasca for Aaron Rodgers, LSD for A$AP Rocky: 17 Celebrities Who've Used Psychedelics
Celebrities like Aaron Rodgers and Kristen Bell are increasingly sharing their experiences with psychedelics for healing and self-discovery, highlighting therapeutic benefits such as reduced anxiety and depression. Despite potential risks and legal issues, research supports psychedelics' positive effects on mental health and creativity, with some advocating for regulated therapeutic use.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath